羟苯磺酸钙联合缬沙坦治疗高血压合并2型糖尿病肾病患者的效果

Effects of Calcium dobesilate combined with Valsartan in treatment of patients with hypertension complicated with type 2 diabetic nephropathy

目的:观察羟苯磺酸钙联合缬沙坦治疗高血压合并2型糖尿病肾病患者的效果。方法:选取2021年12月至2022年12月该院收治的80例高血压合并2型糖尿病肾病患者进行前瞻性研究,按照数字随机表法将其分为对照组和观察组各40例。两组均予以控制血糖、血压治疗,在此基础上,对照组予以缬沙坦治疗,观察组在对照组基础上联合羟苯磺酸钙治疗,两组均连续治疗12周。比较两组临床疗效,治疗前后肾功能指标[尿白蛋白/肌酐比值(UACR)、内生肌酐清除率(Ccr)]水平、血管内皮因子[血管内皮生长因子(VEGF)、内皮素-1(ET-1)]水平、碳水化合物反应元件结合蛋白(ChREBP)水平、人分泌型卷曲相关蛋白5(Sfrp5)水平,以及不良反应发生率。结果:观察组治疗总有效率为97.50%(39/40),高于对照组的80.00%(32/40),差异有统计学意义(P<0.05);治疗后,观察组UACR、VEGF、ET-1、ChREBP水平均低于对照组,Ccr、Sfrp5水平均高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:羟苯磺酸钙联合缬沙坦治疗高血压合并2型糖尿病肾病患者可提高治疗总有效率和Sfrp5水平,改善肾功能指标水平,降低血管内皮因子水平和ChREBP水平,效果优于单纯缬沙坦治疗。

Objective:To observe effects of Calcium dobesilate combined with Valsartan in treatment of patients with hypertension complicated with type 2 diabetic nephropathy.Methods:A prospective study was conducted on 80 patients with hypertension and type 2 diabetic nephropathy admitted to this hospital from December 2021 to December 2022.They were divided into control group and observation group according to the digital random table method,40 cases in each.Both groups were treated with blood glucose and blood pressure control.On this basis,the control group was treated with Valsartan,while the observation group was treated with Calcium dobesilate on the basis of that of the control group.Both groups were treated continuously for 12 weeks.The clinical efficacy,the renal function indexes[urinary albumin/creatinine ratio(UACR),endogenous creatinine clearance rate(Ccr)]levels,the vascular endothelial factors[vascular endothelial growth factor(VEGF),endothelin-1(ET-1)]levels,the carbohydrate response element binding protein(ChREBP)level,the human secreted frizzled-related protein 5(Sfrp5)level,and incidence of adverse reactions were compared between the two groups levels before and after the treatment.Results:The total effective rate of the observation group was 97.50%(39/40),which was higher than 80.00%(32/40)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of UACR,VEGF,ET-1 and ChREBP in the observation group were lower than those in the control group,the levels of Ccr and Sfrp5 were higher than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Calcium dobesilate combined with Valsartan can improve the total effective rate and the Sfrp5 levels,improve the levels of renal function indexes,and reduce the levels of vascular endothelial factors and ChREBP in the patients with hypertension complicated with type 2 diabetic nephropathy.Moreover,it is superior to single Valsartan treatment.